Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells

Signe R Michaelsen; Camilla L Christensen; Maxwell Sehested; Frederik Cramer; Thomas T Poulsen; Adam V Patterson; Hans S Poulsen

doi:10.1002/jgm.2630

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells

Signe R Michaelsen
, Camilla L Christensen
, Maxwell Sehested
, Frederik Cramer
, Thomas T Poulsen
, Adam V Patterson
, Hans S Poulsen

Afdeling for Patologi DIA

15 Citationer (Scopus)

Abstract

Transcriptional targeted suicide gene (SG) therapy driven by the insulinoma-associated 1 (INSM1) promoter makes it possible to target suicide toxin production and cytotoxicity exclusively to small cell lung cancer (SCLC) cells and tumors. It remains to be determined whether acquired chemoresistance, as observed in the majority of SCLC patients, desensitizes SCLC cells to INSM1 promoter-driven SG therapy.

Originalsprog	Engelsk
Tidsskrift	The journal of gene medicine
Vol/bind	14
Udgave nummer	7
Sider (fra-til)	445-58
Antal sider	14
ISSN	1943-961X
DOI	https://doi.org/10.1002/jgm.2630
Status	Udgivet - 2012

Adgang til dokumentet

10.1002/jgm.2630

Citationsformater

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells. / Michaelsen, Signe R; Christensen, Camilla L; Sehested, Maxwell et al.
I: The journal of gene medicine, Bind 14, Nr. 7, 2012, s. 445-58.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{f622ced20cca46449e70787c102858a8,

title = "Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells",

abstract = "Transcriptional targeted suicide gene (SG) therapy driven by the insulinoma-associated 1 (INSM1) promoter makes it possible to target suicide toxin production and cytotoxicity exclusively to small cell lung cancer (SCLC) cells and tumors. It remains to be determined whether acquired chemoresistance, as observed in the majority of SCLC patients, desensitizes SCLC cells to INSM1 promoter-driven SG therapy.",

keywords = "Animals, Apoptosis, Cell Line, Tumor, Cell Survival, Chemotherapy, Adjuvant, Cytosine Deaminase, Drug Resistance, Neoplasm, Drug Therapy, Combination, Escherichia coli, Flucytosine, Genes, Transgenic, Suicide, Genetic Therapy, Humans, Lung Neoplasms, Male, Mice, Nitroreductases, Pentosyltransferases, Promoter Regions, Genetic, Repressor Proteins, Small Cell Lung Carcinoma, Yeasts",

author = "Michaelsen, \{Signe R\} and Christensen, \{Camilla L\} and Maxwell Sehested and Frederik Cramer and Poulsen, \{Thomas T\} and Patterson, \{Adam V\} and Poulsen, \{Hans S\}",

note = "Copyright {\textcopyright} 2012 John Wiley \& Sons, Ltd.",

year = "2012",

doi = "10.1002/jgm.2630",

language = "English",

volume = "14",

pages = "445--58",

journal = "The journal of gene medicine",

issn = "1943-961X",

publisher = "Sequence Medical LLC",

number = "7",

}

TY - JOUR

T1 - Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells

AU - Michaelsen, Signe R

AU - Christensen, Camilla L

AU - Sehested, Maxwell

AU - Cramer, Frederik

AU - Poulsen, Thomas T

AU - Patterson, Adam V

AU - Poulsen, Hans S

PY - 2012

Y1 - 2012

N2 - Transcriptional targeted suicide gene (SG) therapy driven by the insulinoma-associated 1 (INSM1) promoter makes it possible to target suicide toxin production and cytotoxicity exclusively to small cell lung cancer (SCLC) cells and tumors. It remains to be determined whether acquired chemoresistance, as observed in the majority of SCLC patients, desensitizes SCLC cells to INSM1 promoter-driven SG therapy.

AB - Transcriptional targeted suicide gene (SG) therapy driven by the insulinoma-associated 1 (INSM1) promoter makes it possible to target suicide toxin production and cytotoxicity exclusively to small cell lung cancer (SCLC) cells and tumors. It remains to be determined whether acquired chemoresistance, as observed in the majority of SCLC patients, desensitizes SCLC cells to INSM1 promoter-driven SG therapy.

KW - Animals

KW - Apoptosis

KW - Cell Line, Tumor

KW - Cell Survival

KW - Chemotherapy, Adjuvant

KW - Cytosine Deaminase

KW - Drug Resistance, Neoplasm

KW - Drug Therapy, Combination

KW - Escherichia coli

KW - Flucytosine

KW - Genes, Transgenic, Suicide

KW - Genetic Therapy

KW - Humans

KW - Lung Neoplasms

KW - Male

KW - Mice

KW - Nitroreductases

KW - Pentosyltransferases

KW - Promoter Regions, Genetic

KW - Repressor Proteins

KW - Small Cell Lung Carcinoma

KW - Yeasts

U2 - 10.1002/jgm.2630

DO - 10.1002/jgm.2630

M3 - Journal article

C2 - 22576955

SN - 1943-961X

VL - 14

SP - 445

EP - 458

JO - The journal of gene medicine

JF - The journal of gene medicine

IS - 7

ER -

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater